FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111807830> ?p ?o ?g. }

• W2111807830 endingPage "2164" @default.
• W2111807830 startingPage "2158" @default.
• W2111807830 abstract "Abstract The ability of cancer cells to undergo invasion and migration is a prerequisite for tumor metastasis. Rho, a Ras-related small GTPase, and the Rho-associated coiled coil–containing protein kinases (Rho kinases, ROCK1 and ROCK2) are key regulators of focal adhesion, actomyosin contraction, and thus cell motility. Inhibitors of this pathway have been shown to inhibit tumor cell motility and metastasis. Here, we show that fasudil [1-(5-isoquinolinesulfonyl)-homopiperazine], an orally available inhibitor of Rho kinases, and its metabolite 1-(hydroxy-5-isoquinoline sulfonyl-homopiperazine) (fasudil-OH) modify tumor cell morphology and inhibit tumor cell migration and anchorage-independent growth. In addition, we show that fasudil inhibited tumor progression in three independent animal models. In the MM1 peritoneal dissemination model, tumor burden and ascites production were reduced by &gt;50% (P &lt; 0.05). In the HT1080 experimental lung metastasis model, fasudil decreased lung nodules by ∼40% (P &lt; 0.05). In the orthotopic breast cancer model with MDA-MB-231, there were 3-fold more tumor-free mice in the fasudil-treated group versus saline control group (P &lt; 0.01). Fasudil has been approved for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms. In patients, fasudil is well tolerated without any serious adverse reactions. Therefore, the concept of Rho kinase inhibition as an antimetastatic therapy for cancer can now be clinically explored. [Mol Cancer Ther 2006;5(9):2158–64]" @default.
• W2111807830 created "2016-06-24" @default.
• W2111807830 creator A5006976615 @default.
• W2111807830 creator A5024892252 @default.
• W2111807830 creator A5031820960 @default.
• W2111807830 creator A5033098447 @default.
• W2111807830 creator A5053772069 @default.
• W2111807830 creator A5058132261 @default.
• W2111807830 creator A5063623080 @default.
• W2111807830 creator A5069002092 @default.
• W2111807830 creator A5072628042 @default.
• W2111807830 creator A5076010228 @default.
• W2111807830 date "2006-09-01" @default.
• W2111807830 modified "2023-10-16" @default.
• W2111807830 title "The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models" @default.
• W2111807830 cites W1839381104 @default.
• W2111807830 cites W1867653098 @default.
• W2111807830 cites W1964678604 @default.
• W2111807830 cites W1967784028 @default.
• W2111807830 cites W1980751371 @default.
• W2111807830 cites W1987355878 @default.
• W2111807830 cites W1991032022 @default.
• W2111807830 cites W2000060365 @default.
• W2111807830 cites W2008261978 @default.
• W2111807830 cites W2010779754 @default.
• W2111807830 cites W2016955748 @default.
• W2111807830 cites W2029221632 @default.
• W2111807830 cites W2034316434 @default.
• W2111807830 cites W2054365538 @default.
• W2111807830 cites W2071360568 @default.
• W2111807830 cites W2075204296 @default.
• W2111807830 cites W2077221186 @default.
• W2111807830 cites W2077979328 @default.
• W2111807830 cites W2091726521 @default.
• W2111807830 cites W2100547571 @default.
• W2111807830 cites W2102867120 @default.
• W2111807830 cites W2116007831 @default.
• W2111807830 cites W2117519868 @default.
• W2111807830 cites W2132052155 @default.
• W2111807830 cites W2138742704 @default.
• W2111807830 cites W2334663452 @default.
• W2111807830 cites W2375169070 @default.
• W2111807830 doi "https://doi.org/10.1158/1535-7163.mct-05-0440" @default.
• W2111807830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16985048" @default.
• W2111807830 hasPublicationYear "2006" @default.
• W2111807830 type Work @default.
• W2111807830 sameAs 2111807830 @default.
• W2111807830 citedByCount "168" @default.
• W2111807830 countsByYear W21118078302012 @default.
• W2111807830 countsByYear W21118078302013 @default.
• W2111807830 countsByYear W21118078302014 @default.
• W2111807830 countsByYear W21118078302015 @default.
• W2111807830 countsByYear W21118078302016 @default.
• W2111807830 countsByYear W21118078302017 @default.
• W2111807830 countsByYear W21118078302018 @default.
• W2111807830 countsByYear W21118078302019 @default.
• W2111807830 countsByYear W21118078302020 @default.
• W2111807830 countsByYear W21118078302021 @default.
• W2111807830 countsByYear W21118078302022 @default.
• W2111807830 countsByYear W21118078302023 @default.
• W2111807830 crossrefType "journal-article" @default.
• W2111807830 hasAuthorship W2111807830A5006976615 @default.
• W2111807830 hasAuthorship W2111807830A5024892252 @default.
• W2111807830 hasAuthorship W2111807830A5031820960 @default.
• W2111807830 hasAuthorship W2111807830A5033098447 @default.
• W2111807830 hasAuthorship W2111807830A5053772069 @default.
• W2111807830 hasAuthorship W2111807830A5058132261 @default.
• W2111807830 hasAuthorship W2111807830A5063623080 @default.
• W2111807830 hasAuthorship W2111807830A5069002092 @default.
• W2111807830 hasAuthorship W2111807830A5072628042 @default.
• W2111807830 hasAuthorship W2111807830A5076010228 @default.
• W2111807830 hasBestOaLocation W21118078301 @default.
• W2111807830 hasConcept C121608353 @default.
• W2111807830 hasConcept C126322002 @default.
• W2111807830 hasConcept C133717845 @default.
• W2111807830 hasConcept C184235292 @default.
• W2111807830 hasConcept C185592680 @default.
• W2111807830 hasConcept C201800478 @default.
• W2111807830 hasConcept C2776048814 @default.
• W2111807830 hasConcept C2777093181 @default.
• W2111807830 hasConcept C2778609687 @default.
• W2111807830 hasConcept C2779013556 @default.
• W2111807830 hasConcept C2779256057 @default.
• W2111807830 hasConcept C2779331819 @default.
• W2111807830 hasConcept C502942594 @default.
• W2111807830 hasConcept C55493867 @default.
• W2111807830 hasConcept C58207958 @default.
• W2111807830 hasConcept C62478195 @default.
• W2111807830 hasConcept C71924100 @default.
• W2111807830 hasConcept C86803240 @default.
• W2111807830 hasConcept C95444343 @default.
• W2111807830 hasConcept C97029542 @default.
• W2111807830 hasConcept C98274493 @default.
• W2111807830 hasConceptScore W2111807830C121608353 @default.
• W2111807830 hasConceptScore W2111807830C126322002 @default.
• W2111807830 hasConceptScore W2111807830C133717845 @default.
• W2111807830 hasConceptScore W2111807830C184235292 @default.
• W2111807830 hasConceptScore W2111807830C185592680 @default.

• next